Cost-Effectiveness of Aripiprazole Tablets with Sensor versus Oral Atypical Antipsychotics for the Treatment of Schizophrenia Using a Patient-Level Microsimulation Modeling Approach

References

• Marder SR, Cannon TD, Ropper AH. Schizophrenia. N Engl J Med. 2019;381(18):1753–1761. doi:10.1056/NEJMra1808803
   PubMed Web of Science ®Google Scholar
• Kessler RC, Birnbaum H, Demler O, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005;58(8):668–676. doi:10.1016/j.biopsych.2005.04.034
   PubMed Web of Science ®Google Scholar
• Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):1535–1540. doi:10.1017/S0033291706008191
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Schizophrenia; 2020. Available from: https://www.nimh.nih.gov/health/statistics/schizophrenia. Accessed May 3, 2023.
   Google Scholar
• Tsai J, Rosenheck RA. Psychiatric comorbidity among adults with schizophrenia: a latent class analysis. Psychiatry Res. 2013;210(1):16–20. doi:10.1016/j.psychres.2013.05.013
   PubMed Web of Science ®Google Scholar
• Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–1181. doi:10.1001/jamapsychiatry.2015.1737
   PubMed Web of Science ®Google Scholar
• Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247–253. doi:10.1001/archpsyc.62.3.247
   PubMed Web of Science ®Google Scholar
• Schoenbaum M, Sutherland JM, Chappel A, et al. Twelve-month health care use and mortality in commercially insured young people with incident psychosis in the United States. Schizophr Bull. 2017;43(6):1262–1272. doi:10.1093/schbul/sbx009
   PubMed Web of Science ®Google Scholar
• Simon GE, Stewart C, Yarborough BJ, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry. 2018;75(3):254–260. doi:10.1001/jamapsychiatry.2017.4437
   PubMed Web of Science ®Google Scholar
• Cloutier M, Sanon Aigbogun M, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764–771. doi:10.4088/JCP.15m10278
   PubMed Web of Science ®Google Scholar
• Keepers GA, Fochtmann LJ, Anzia JM, et al. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872. doi:10.1176/appi.ajp.2020.177901
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1–3):83–92. doi:10.1016/j.schres.2010.11.020
   PubMed Web of Science ®Google Scholar
• Au-Yeung KY, Moon GD, Robertson TL, et al. Early clinical experience with networked system for promoting patient self-management. Am J Manag Care. 2011;17(7):e277–e287.
   PubMed Web of Science ®Google Scholar
• Hatch A, Docherty JP, Carpenter D, et al. Expert consensus survey on medication adherence in psychiatric patients and use of a digital medicine system. J Clin Psychiatry. 2017;78(7):e803–e812. doi:10.4088/JCP.16m11252
   PubMed Web of Science ®Google Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62. doi:10.2147/PROM.S42735
   PubMedGoogle Scholar
• Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther. 2013;30(3):286–297. doi:10.1007/s12325-013-0016-5
   PubMed Web of Science ®Google Scholar
• Kaufman N. Digital therapeutics: leading the way to improved outcomes for people with diabetes. Diabetes Spectr. 2019;32(4):301–303. doi:10.2337/ds19-0012
   PubMedGoogle Scholar
• Knights J, Heidary Z, Peters-Strickland T, et al. Evaluating digital medicine ingestion data from seriously mentally ill patients with a bayesian hybrid model. NPJ Digit Med. 2019;2(1):20. doi:10.1038/s41746-019-0095-z
   PubMed Web of Science ®Google Scholar
• Cohen EA, Skubiak T, Boskovic DH, et al. Phase 3b multicenter, prospective, open-label trial to evaluate the effects of a digital medicine system on inpatient psychiatric hospitalization rates for adults with schizophrenia. J Clin Psychiatry. 2022;83(3). doi:10.4088/JCP.21m14132
   Web of Science ®Google Scholar
• LaViola JJ. Double exponential smoothing: an alternative to Kalman filter-based predictive tracking.2003:199–206. doi:10.1145/769953.769976
   Google Scholar
• Canfield SL, Zuckerman A, Anguiano RH, et al. Navigating the wild west of medication adherence reporting in specialty pharmacy. J Manag Care Spec Pharm. 2019;25(10):1073–1077. doi:10.18553/jmcp.2019.25.10.1073
   PubMed Web of Science ®Google Scholar
• International Business Machines. Micromedex® RED BOOK; 2020. Available from: https://www.micromedexsolutions.com/home/dispatch/ssl/true. Accessed May 3, 2023.
   Google Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Econ. 2013;16(7):917–925. doi:10.3111/13696998.2013.804411
   PubMedGoogle Scholar
• Ignatova D, Kamusheva M, Petrova G, et al. Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria. Soc Psychiatry Psychiatr Epidemiol. 2019;54(11):1353–1362. doi:10.1007/s00127-019-01700-2
   PubMed Web of Science ®Google Scholar
• United States Department of Labor. Usual weekly earnings of wage and salary workers second quarter 2021; 2021. Available from: https://www.bls.gov/news.release/pdf/wkyeng.pdf. Accessed May 3, 2023.
   Google Scholar
• Federal Reserve Economic Data. Consumer price index for all urban consumers: medical care in U.S. city average; 2021. Available from: https://fred.stlouisfed.org/series/CPIMEDSL. Accessed May 3, 2023.
   Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192–213. doi:10.1093/schbul/sbs150
   PubMed Web of Science ®Google Scholar
• Liang SG, Greenwood TA. The impact of clinical heterogeneity in schizophrenia on genomic analyses. Schizophr Res. 2015;161(2–3):490–495. doi:10.1016/j.schres.2014.11.019
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15(6):796–803. doi:10.1016/j.jval.2012.06.012
   PubMed Web of Science ®Google Scholar
• Statistics Canada. Microsimulation approaches; 2016. Available from: https://www.statcan.gc.ca/en/microsimulation/modgen/new/chap2/chap2. Accessed May 3, 2023.
   Google Scholar
• Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295–1310. doi:10.1002/hec.1148
   PubMed Web of Science ®Google Scholar
• Kreke JE, Schaefer AJ, Roberts MS. Simulation and critical care modeling. Curr Opin Crit Care. 2004;10(5):395–398. doi:10.1097/01.ccx.0000139361.30327.20
   PubMedGoogle Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Med Decis Making. 2012;32(5):690–700. doi:10.1177/0272989X12455463
   PubMed Web of Science ®Google Scholar
• Davis S, et al. In NICE DSU Technical Support Document 15: Cost-Effectiveness Modelling Using Patient-Level Simulation. London: National Institute for Health and Care Excellence (NICE); 2014.
   Google Scholar
• Ascher-Svanum H, Furiak NM, Lawson AH, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Econ. 2012;15(3):531–547. doi:10.3111/13696998.2012.662923
   PubMedGoogle Scholar
• Lin Z, Xuan J. Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China. Expert Rev Pharmacoecon Outcomes Res. 2020;20(5):549–557. doi:10.1080/14737167.2020.1807331
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009;7(1):4. doi:10.1186/1478-7547-7-4
   PubMedGoogle Scholar
• Dilla T, Ciudad A, Alvarez Á. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence. 2013;78:e803–e812. doi:10.2147/PPA.S41609
   Google Scholar
• Jin H, Tappenden P, MacCabe JH, et al. Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations. Br J Psychiatry. 2020;1–6 . doi:10.1192/bjp.2020.241
   Web of Science ®Google Scholar
• McCoy CE. Understanding the intention-to-treat principle in randomized controlled trials. West J Emerg Med. 2017;18(6):1075–1078. doi:10.5811/westjem.2017.8.35985
   PubMed Web of Science ®Google Scholar
• Citrome L, Kamat SA, Sapin C, et al. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. J Med Econ. 2014;17(8):567–576. doi:10.3111/13696998.2014.917089
   PubMedGoogle Scholar
• Sicras-Mainar A, Maurino J, Ruiz-Beato E, et al. Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study. BMC Psychiatry. 2014;14(1):225. doi:10.1186/s12888-014-0225-8
   PubMedGoogle Scholar